



Company Presentation

October, 2018



Ofer Haviv, President & CEO

Safe Harbor Statement



This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disdains any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

- Introduction
- Ag Divisions
- Subsidiaries
- Technology
- Summary

What We Do

We develop novel products for life-science markets...

...through the use of a unique *Computational Predictive Biology (CPB)* platform



Evogene at a Glance...

An innovative, *Computationally Predictive Biology* (CPB) platform –

creation, integration and analysis of dedicated Big-Data for predictive biological discoveries

Currently applied to identify:

- Chemical compounds for innovative Ag-Chemicals
- Genetic elements for improved Seed Traits
- Microbes for novel Ag-Biologicals
- Microbes for Human Therapeutics

Collaborations with world-leading agriculture companies through the years


Targeted Markets: Ag-Chemicals, Seed Traits, Ag-Biologicals, Industrial Oils and Microbiome based Human Therapeutics

Revenue model - based on licensing agreements, which typically include three main revenue streams:

- R&D payments
- Milestone payments
- Royalties and other revenue sharing from product sales

Financial fundamentals -


- Cash position - \$62.3 million (June 30th, 2018), no debt
- Listed on TASE (2007) and NASDAQ (2013)



Evogene – An Evolving Story

Evogene activity at 2013 NYSE IPO


2007-2013



Evogene – An Evolving Story

Evogene's activity in 2018

2018 - Onward




- Introduction
- Ag Divisions
- Subsidiaries
- Technology
- Summary

Agriculture Market Challenges




As global population grows...

World Population



Arable land (hectares per person)




...food production is faced with major challenges


Soaring resistance to herbicides

Heavier regulations, increasing awareness to environment


Decline in new product introduction



New Active Ingredient Introductions 1980-2016



Improve and secure crop yields by:



Ag Chemicals -

Market: \$50B* (2016), expected to reach \$70B* (2022)

Product types: Herbicides, Insecticides, Fungicides and Crop Enhancers

Innovation differentiator: Protein targets and small molecules



Seed -

Market: \$37B* (2015)

Product types: Seed traits with improve yields and abiotic stress tolerance, disease resistance, insect control and quality traits

Innovation differentiator : Genes, Edits and other genomic elements




Ag Biologicals -

Market: \$3B* (2015), expected to reach \$8B* (2022)

Product types: Bio-stimulants, Bio-insecticides and Bio-fungicides

Innovation differentiator : Mainly microbes



Mission: Discover and optimize novel & safe Ag-chemical products, leveraging biology-driven computational chemistry

Products under development:




Herbicides –Market size: \$21B* (2016), growing market need for novel herbicides with improved safety profile and solution for increasing resistance to current herbicides




Insecticides - Market size: \$14B* (2016), growing market need for improved insecticide selectivity and solution for increasing resistance to current insecticides

Ag-Chemicals - Pipeline



<u>Herbicides</u>					
Novel herbicides**					
Novel herbicides		Phase undisclosed			
AI optimization					
<u>Insecticides</u>					
Novel insecticides**					
Novel insecticides		Phase undisclosed			



AI-Active Ingredient

Target- Vital proteins in pests

Hit- Active chemical compound

Lead- optimal product candidate


* Timeline according to industry estimates

** Multiple targets


Ag-Chemicals - Select Results: Novel Herbicides

Example for Chemical Hit Displaying Herbicidal Activity in Greenhouse

**Commercial
herbicide** (positive
control)



EVO AG1345*



No treatment
(negative
control)




*Initial results before optimization

Example of Efficacy Optimization of Chemical Hits on Weeds (Y 2017)

Molecule

Molecule Optimization



Dosage

Ag-Chemicals - Collaboration Example: BASF

- Initiated in 2015, collaboration period - 3 years

- Objective – BASF and Evogene announce multiyear collaboration for the development of novel insecticides
- Activities:

- Evogene to identify candidate


- BASF to support development

The collaboration achieved its first milestone

Ludwigshafen, Germany and Rehovot, Israel – May 29, 2018 – BASF, one of the world's leading chemical companies, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today a new collaboration focusing on the development of novel insecticides based on new binding areas (Site-of-Action or 'SoA') on key insecticidal target proteins. The parties also announced that the collaboration achieved its first project milestone, with the joint nomination of a set of novel SoAs, discovered by Evogene that will advance to the discovery phase of relevant bioactive compounds.

Target and

cialization



CPB

Targets & chemicals




Chemical screens


Chemical hits



Development, regulation & registration



Innovative Herbicide



Mission: Bring to market top-quality seeds with high-value traits, under the “Triple S” Concept – Safe, Secure and Sustainable food

Products under development mainly via (i) GMO and (ii) Genome Editing :



Yield and environmental stress traits- Yield, drought, nitrogen usage efficiency




Disease resistance traits- Fusarium, Black Sigatoka, Asian Rust, Nematodes



Insect control traits- Lepidoptera, Coleoptera, Hemiptera



- (i) **GMO** - genetically modified organism: an organism whose genetic material has been altered by means of genetic engineering
- (ii) **Genome Editing** - edits made to the existing genome

Ag Seeds - Pipeline: Main GMO Product Candidates*



Ag Seeds - Insect Control Active - Example

Model plant - leaf assay with cotton leafworm



- Active against two lepidopteran species in two different plant systems & against the hemipteran species Soybean aphid
- Progressing into target plants

Ag Seeds - Collaboration Example - Monsanto


- **Collaboration period** - 10 years
- **Objective** - improved seeds via biotechnology
- **Crops** - corn, soybean, cotton, canola
- **Traits** - (i) Yield/drought tolerance/fertilizer utilization
(II) Fusarium resistance in corn
- **Key terms** -
 - R&D and up-front payments - total ~\$68M
 - Milestone payments + royalties from sales
 - \$30M equity investment



Gene discovery and trait optimization



Development and commercialization



CPB



Model plant validation




Target plant validation and development




Improved seeds

Ag Seeds - Pipeline: Main Genome Editing Product Candidates*




Banana with high resistance to the Black Sigatoka fungus showing positive results (Y2014, Y2016)

- 8 Genes showed repeated increased resistance in two separate banana field trials
- Positive results were observed with zero fumigation
- Leveraging validated genes with positive results to genome editing product development



*Timeline according to industry estimates



Mission: Improving agriculture productivity and sustainability through the introduction of microbiome based Ag-Biologicals

Products under development:



Bio-Stimulant – Market size: \$2B* (2016), Microbial based targeting yield improvement in row crops such as corn, wheat



Bio- Pesticides (Bio-Insecticides & Bio-Fungicides) - Market size: \$1.2B* (2016), Microbial based treatments, targeting insects (corn rootworm, stinkbug and lepidoptera) and fungi (fusarium and mildew)

Ag-Biologicals - Pipeline



*Timeline according to industry estimates

Ag-Biologicals - Select Results: Corn Bio-Stimulants

10% Yield improvement in field trials (2016, 2017)

Under moderate drought


EVO004





None - inoculated



None - inoculated



EVO004




Ag-Biologicals - Collaboration Example: Corteva*

- Initiated in 2017
- Objective - Develop and commercialize microbiome based bio-stimulant products that improve corn yield
- Current stage - Early development
- Activities -
 - Evogene and Corteva to further develop candidate products in target regions in the US
 - Corteva to commercialize products through its world-leading seed treatment business



Agenda

- Introduction
- Ag Divisions
- Subsidiaries
- Technology
- Summary



Mission: providing castor seeds & ag-service solutions for the castor oil and derivatives industry




Activities


- Develop elite castor varieties - advanced breeding technology and genomics
- Seed production- Castor bean fields for the production of seeds
- Agro-technical support- Market specific crop protocols
- Mechanical harvesting solution support

Evofuel targets South America





Mission: discovery and development of human microbiome based therapeutics




Activities

- Immuno-oncology (with ICI) – combination therapy for cancer
- MDRO (Multi Drug resistant organisms) – targeting antibiotic resistant bacteria
- CI related disorders - GI inflammatory & functional disorders

Human Microbiome Based Drugs Market

Projected Global Market for Human Microbiome-Based Drugs and Diagnostics



Sources:

BCC Research (2017) – Human Microbiome-based Drugs and Diagnostics Market. SVB – (Emerging Healthcare: Microbiome Investment Trends Aug 2017)

~\$ 10Bn market opportunity by 2024

\$840M invested in microbiome space since 2010


Big pharma and VCs deeply engaged

Agenda

- Introduction
- Ag Divisions
- Subsidiaries
- Technology
- Summary


Evogene's Unique Product Development Approach

The increasing number of criteria for successful product launch have made traditional linear methodology inefficient




Evogene's Unique Product Development Approach


The increasing number of criteria for successful product launch have made traditional linear methodology inefficient



What is Required of Such a Platform?




The CPB Platform – From Vision to Reality



Agenda

- Introduction
- Ag Divisions
- Subsidiaries
- Technology
- Summary

Corporate Structure & Business Unit Managers



1

Unique technology platform (CPB), combining expertise in life science and cutting-edge computational technology – *'Connecting the Dots'*

2

Engine for next generation product for life science - targeting multi-billion dollar markets

3

Innovation partner-of-choice for industry leaders

4

Diversified product portfolio with clear paths to milestone payments and royalties

5

Strong balance sheet



Short term catalysts: (i) additional collaborations, (ii) phase advancements in existing product programs, (iii) R&D fees and milestone payments



Thank You

Contact:

investors@evogene.com

T: +972 8 931 1934

Appendix - Financials

Key Financials – Balance Sheet

Thousand US \$	30.06.2018	30.06.2017
Current Assets	64,083	87,446
Long-Term Assets	4,007	5,625
Total Assets	68,090	87,446
Current Liabilities	4,946	4,633
Long-Term Liabilities	3,191	3,478
Shareholders Equity	59,953	79,335
Total Liabilities & Shareholders Equity	68,090	87,446

Key Points:

- Cash position: ~62.3 million USD as of 30.06.2018
- No debt
- Estimated net cash usage for 2018: \$14-\$16 million

Key Financials – P&L

Thousand US \$	H1 2018	H1 2017	2017
Revenues	745	1,899	3,381
Gross Profit	196	234	536
Operating Loss	(9,619)	(10,426)	(21,947)
Loss	(10,155)	(9,590)	(20,838)

Key Points:

- Revenues consist primarily of R&D revenues, reflecting cost reimbursement under our collaboration agreements
- Advancement of our collaboration agreement with Monsanto reducing R&D revenues